Controlling Sexually Transmitted Disease May Not Lower HIV Infection Rates

June 30, 1998

A large clinical trial in a Ugandan population heavily infected with the human immunodeficiency virus (HIV) has shown that despite reductions in sexually transmitted diseases (STDs), HIV incidence was not reduced by STD control measures. The findings, by scientists from the Johns Hopkins Schools of Public Health and Medicine, contradicted those of an earlier study in Mwamza, Tanzania, which found that the rate of HIV infection was 38 percent lower after symptomatic STDs were treated in clinics.

Although scientists have long suspected an association between HIV and STDs, the connection remains elusive. Senior author Ronald H. Gray, professor, Population Dynamics, the Johns Hopkins School of Public Health, said, "Given the significant impact that our mass treatment campaign in Uganda had on STDs, it's disappointing to find no differences in HIV incidence between the treated and untreated populations."

The study, which enrolled a total of 15,127 HIV-negative subjects, was conducted in Rakai District, a rural region in southwestern Uganda with a high prevalence of HIV infection (15.9 percent). In the intervention arm of the trial, the scientists brought an intensive STD control strategy into participants' homes and provided entire communities with broad-spectrum antibiotic treatment for STDs ("mass treatment").

Control-arm subjects whose blood tests revealed syphilis, or who reported current STD symptoms during the interviews, were referred during the 10-monthly visits for free treatment provided by the project itself.

At follow-up after mass STD treatment, the prevalences of syphilis, trichomonas, bacterial vaginosis, gonorrhea, and chlamydia were lower in the intervention arm compared to the control arm; and these differences were particularly marked and statistically significant among pregnant women. Despite these significant differences in STD rates realized between study arms, STD control had no effect on HIV incidence, and HIV incidence was especially high in pregnant women. In contrast, a trial in Mwamza, Tanzania, found a 38 percent lower HIV incidence among subjects receiving clinic-based treatment for symptomatic STDs.

The scientists think it unlikely that problems in study design or follow-up account for the failure to lower HIV incidence in the Rakai district. Treatment coverage was high. Over 80 percent of all eligible adults in the communities (and over 90 percent of those enrolled) accepted treatment. The researchers felt that the fact that STD services were offered to control subjects would not explain the absence of any effect on HIV, since few symptomatic persons used these services.

Gray said that "our data show that STDs increase the risk of HIV infections at an individual level, but with the high background prevalence of HIV, most HIV transmission occurs independently of STD transmission."

The earlier Mwamza trial involved a population with an HIV infection rate of 4.1 percent, whereas the epidemic in Rakai was "mature," with 15.9 percent of the population HIV-positive. Gray said, "This trial raises important questions with regard to future policies on STD control and HIV prevention and thus it is imperative to determine whether the divergent findings between our trial and the one in Mwamza reflect differences in the stage of the two HIV epidemics." Gray called for a collaborative reassessment by the two research teams, as well as new trials in regions where HIV incidence is high and where it is low.
-end-
The study was supported by grants from the National Institute of Allergy and Infectious Diseases; the National Institute of Child Health and Development; the U.S. National Institutes of Health; the Rockefeller Foundation; and the World Bank Uganda STI Project and John Snow Inc.

Contact: Marc Kusinitz (44-77-71-706961)

Lisbeth Pettengill lpetteng@jhsph.edu
-end-


Johns Hopkins University Bloomberg School of Public Health

Related HIV Articles from Brightsurf:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.

Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.

The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.

Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.

NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.

Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.

Read More: HIV News and HIV Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.